Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Breast Neoplasms 92Polycystic Ovary Syndrome 11Neoplasm Metastasis 7Infertility 5Carcinoma, Ductal, Breast 5Carcinoma, Lobular 4Osteoporosis 3Neoplasms, Hormone-Dependent 3Neoplasms 3Breast Neoplasms, Male 3Advanced Breast Cancer 3Fallopian Tube Neoplasms 2Carcinoma, Ovarian Epithelial 2Breast Carcinoma In Situ 2Bone Diseases, Metabolic 2Unilateral Breast Neoplasms 1Recurrence 1Peritoneal Neoplasms 1Ovarian Neoplasms 1Osteitis Deformans 1Obesity 1Neoplasms by Site 1Multiple Endocrine Neoplasia Type 1 1Low Grade Serous Ovarian Cancer 1Infertility, Female 1Hormone Receptor-Positive and HER2-Negative Advanced Breast Cancer 1Hereditary Sensory and Autonomic Neuropathies 1Hereditary Breast and Ovarian Cancer Syndrome 1HR+/HER2- Breast Cancer 1HER2+ Breast Cancer 1

Interventions

Zoledronic Acid 3Denosumab 3Vitamin D 2Risedronic Acid 2Letrozole 2Toremifene 1Ibandronic Acid 1Geritol 1Calcium Carbonate 1Calcium 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Bone Diseases, Metabolic × Letrozole × Clear all
NCT00050011 2014-03-21

Zoledronic Acid - Letrozole Adjuvant Synergy Trial (ZFAST) - Cancer Treatment Related Bone Loss in Postmenopausal Women With Estrogen Receptor Positive and/or Progesterone Receptor Positive Breast Cancer Receiving Adjuvant Hormonal Therapy

Novartis

Phase 3 Completed
602 enrolled 13 charts
Breast

Bone Diseases, Metabolic, Breast Neoplasms, Osteoporosis

NCT00171340 2012-04-16

Zoledronic Acid in the Prevention of Cancer Treatment Related Bone Loss in Postmenopausal Women Receiving Letrozole for Breast Cancer.

Novartis

Phase 3 Completed
1,065 enrolled 10 charts
Breast

Bone Diseases, Metabolic, Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡